POSITION STATEMENT

Cannabis-Based Medicinal Products for the Management of Patients with Chronic Pain

Recommendation:

The use of cannabis-based medicinal products in chronic pain is not recommended – RAG status ‘Black’

This guidance does not apply to the use of Sativex® (delta-9-tetrahydrocannabinol and cannabidiol) oromucosal spray as an adjunct treatment for moderate to severe spasticity in multiple sclerosis.

Please note: this is an interim LMMG position pending the publication NICE guidance, expected October 2019.

Background

In June 2018 the Home Office launched a review into the scheduling of cannabis and cannabis-based products for medicinal purposes. The Chief Medical Officer (CMO) for England and Chief Medical Advisor to the UK Government, assessed the therapeutic and medicinal benefits of cannabis-based products for medicinal use in humans on prescription and found that there is conclusive evidence of therapeutic benefit for certain medical conditions, and reasonable evidence in several other medical conditions. Following these recommendations, The Advisory Council on the Misuse of Drugs recommended that “cannabis-derived medicinal products of the appropriate standard” be moved from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations, subject to further refinement of the definition of cannabis-based products for medicinal use. [1]

Guidance for the prescribing of cannabis-based products for chronic pain

The National Institute for Health and Care Excellence (NICE) has been requested by the Department of Health and Social Care to produce a clinical guideline for the prescribing of cannabis-based products for medicinal use in humans. In the interim, the Royal College of Physicians (RCP) has developed additional advice around prescribing of cannabis-based products for medicinal use in chronic pain.

The RCP recommendations state [2]:

“There is no robust evidence for the use of CBPM (cannabis-based products for medicinal use) in chronic pain and their use is not recommended.”

This RCP recommendation is supported by a Cochrane review in March 2018 which concluded, “There is a lack of good evidence that any cannabis-derived product works for any chronic neuropathic pain.” It also concluded that “The potential benefits of cannabis-
based medicine in chronic neuropathic pain might be outweighed by their potential harms.” [2] [3]

Also, a comprehensive meta-analysis of pharmacotherapy for neuropathic pain recommended against the use of cannabinoids in neuropathic pain, the reasons being: negative results, potential misuse, diversion, and long-term mental health risks of cannabis particularly in susceptible individuals. Only two of nine trials of nabiximols in neuropathic pain were positive. [2] [4]


References


Please access this guidance via the LMMG website to ensure that the correct version is in use.

Version Control

<table>
<thead>
<tr>
<th>Version Number</th>
<th>Date</th>
<th>Amendments Made</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>January 2019</td>
<td>New document</td>
<td>PT, AG</td>
</tr>
</tbody>
</table>

©Midlands and Lancashire Commissioning Support Unit, 2019.

The information contained herein may be superseded in due course. All rights reserved.

Produced for use by the NHS, no reproduction by or for commercial organisations, or for commercial purposes, is allowed without express written permission.

Midlands and Lancashire Commissioning Support Unit,

Jubilee House, Lancashire Business Park, Leyland, PR26 6TR

Tel: 01772 644 400 | www.midlandsandlancashirecsu.nhs.uk